RhumbLine Advisers
VRCA icon

RhumbLine Advisers’s Verrica Pharmaceuticals VRCA Stock Holding History

RhumbLine Advisers’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,494
Closed -$15.4K – 4269
2025
Q1 		$15.4K Sell
3,494
-23,115
-87% -$150K ﹤0.01% 3776
2024
Q4 		$186K Buy
26,609
+24,134
+975% +$265K ﹤0.01% 3234
2024
Q3 		$35.9K Sell
2,475
-184
-7% -$8.29K ﹤0.01% 3740
2024
Q2 		$194K Buy
2,659
+451
+20% +$34.6K ﹤0.01% 3239
2024
Q1 		$131K Sell
2,208
-31
-1% -$1.71K ﹤0.01% 3355
2023
Q4 		$164K Sell
2,239
-104
-4% -$4.27K ﹤0.01% 3277
2023
Q3 		$91K Buy
2,343
+291
+14% +$14.8K ﹤0.01% 3494
2023
Q2 		$118K Buy
+2,052
New +$125K ﹤0.01% 3456
2022
Q2 		– Sell
-1,277
Closed -$104K – 3247
2022
Q1 		$104K Sell
1,277
-58
-4% -$4.78K ﹤0.01% 2878
2021
Q4 		$122K Buy
1,335
+37
+3% +$4.19K ﹤0.01% 2916
2021
Q3 		$162K Buy
1,298
+14
+1% +$1.57K ﹤0.01% 2941
2021
Q2 		$145K Sell
1,284
-59
-4% -$7.15K ﹤0.01% 2947
2021
Q1 		$204K Sell
1,343
-66
-5% -$9.13K ﹤0.01% 2825
2020
Q4 		$162K Buy
1,409
+91
+7% +$8.36K ﹤0.01% 2892
2020
Q3 		$102K Sell
1,318
-214
-14% -$17.5K ﹤0.01% 2867
2020
Q2 		$169K Sell
1,532
-201
-12% -$23.2K ﹤0.01% 2829
2020
Q1 		$189K Buy
1,733
+10
+0.6% +$1.32K ﹤0.01% 2608
2019
Q4 		$274K Buy
1,723
+31
+2% +$4.57K ﹤0.01% 2639
2019
Q3 		$250K Buy
1,692
+90
+6% +$10K ﹤0.01% 2663
2019
Q2 		$186K Buy
1,602
+577
+56% +$54.1K ﹤0.01% 2805
2019
Q1 		$111K Buy
+1,025
New +$118K ﹤0.01% 2847

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers's VRCA Position: Q2 2025 in Review

RhumbLine Advisers sold out of Verrica Pharmaceuticals (VRCA) in Q2 2025, closing a stake of 3,494 shares — an estimated $15.4K sold.

RhumbLine Advisers first reported a position in VRCA in Q1 2019 and held it in 21 quarters. The position peaked at $274K in Q4 2019. 58 funds tracked by Wall St. Rank hold VRCA as of Q2 2025.

  • RhumbLine Advisers reported no remaining Verrica Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 3,494 Verrica Pharmaceuticals shares in Q2 2025, an estimated $15.4K.
  • RhumbLine Advisers first reported a position in Verrica Pharmaceuticals in Q1 2019 and held it in 21 quarters.
  • RhumbLine Advisers's Verrica Pharmaceuticals position peaked at $274K in Q4 2019.
  • 58 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.